AI Article Synopsis

  • A retrospective study assessed the effectiveness of crizotinib versus newer ROS1-targeted therapies in patients with advanced non-small-cell lung cancer (NSCLC).
  • Among 49 ROS1-expressing patients, those treated with newer agents like entrectinib and repotrectinib had higher response and disease control rates compared to those treated with crizotinib.
  • Despite crizotinib showing comparable results, the newer therapies demonstrated longer median progression-free survival, highlighting the potential benefits of newer treatment options.

Article Abstract

ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti-cancer agents. Forty-nine ROS1-expressing NSCLC patients, diagnosed with advanced metastatic disease, were included. Molecular profiling using either FISH/CISH or NGS was performed on tissue samples. Twenty-eight patients were treated with crizotinib, while fourteen patients were administered newer drugs (entrectinib, repotrectinib) and seven patients received platinum-doublet chemotherapy in a first-line setting. Overall response rate and disease control rate for the crizotinib and entrectinb/repotrectinib cohort were 68% and 82% vs. 86% and 93%, respectively. Median progression free survival was 1.6 years (95% CI 1.15-2.215) for the crizotinib treatment vs. 2.35 years for the entrectinib/repotrectinib cohort (95% CI 1.19-3.52). Central nervous system progression was noted in 20% and 25% of the crizotinib and entrectinib/repotrectinib cohorts, respectively. This multi-center study presents real-world treatment patterns of ROS1 NSCLC population, indicating that crizotinib exhibited comparable results to entrectinib/repotrectinib in a first-line setting, although both response rate and survival was numerically longer with treatment with newer agents.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11352911PMC
http://dx.doi.org/10.3390/curroncol31080326DOI Listing

Publication Analysis

Top Keywords

non-small-cell lung
8
lung cancer
8
treatment patterns
8
first-line setting
8
setting response
8
response rate
8
crizotinib
6
patients
5
treatment
5
cancer patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!